Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

Overview
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Management of Dysrhythmias in Cardiac Infarction.

Journal of the Royal College of Physicians of London·2019
Same author

Translation of clinical trials into clinical practice.

Journal of internal medicine·2004
Same author

Myocardial infarction: is evidence-based medicine the best?

Lancet (London, England)·2002
Same author

The evolution of the coronary care unit.

Cardiovascular research·2001
Same author

[Legal implications of medical guidelines. A Task Force of the European Society of Cardiology].

Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·2001
Same author

Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT)

Lancet (London, England)·2000

Related Experiment Video

Updated: Jun 13, 2026

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

Comparisons and combinations in anti-anginal therapy.

D G Julian

    European Heart Journal
    |January 1, 1985
    PubMed
    Summary

    Anti-anginal agents offer theoretical treatment options. However, practical choices for angina treatment are influenced by patient factors and often involve trial and error.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Angina pectoris is a complex syndrome requiring effective therapeutic strategies.
    • Multiple classes of anti-anginal medications are available for clinical use.

    Purpose of the Study:

    • To discuss the theoretical basis for selecting anti-anginal agents.
    • To examine the practical considerations influencing anti-anginal drug selection in clinical practice.

    Main Methods:

    • Review of existing literature on anti-anginal agents.
    • Analysis of factors impacting treatment decisions for angina.

    Main Results:

    • Three distinct classes of anti-anginal agents exist, allowing for targeted or combination therapy.
    • Clinical decision-making is frequently influenced by comorbidities, medication costs, and adverse effects.

    More Related Videos

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
    07:25

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

    Published on: May 4, 2017

    Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
    15:04

    Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

    Published on: January 19, 2019

    Related Experiment Videos

    Last Updated: Jun 13, 2026

    Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
    13:42

    Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

    Published on: March 8, 2013

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
    07:25

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

    Published on: May 4, 2017

    Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
    15:04

    Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

    Published on: January 19, 2019

    Conclusions:

    • While theoretical drug selection for angina is possible, practical application necessitates a nuanced approach.
    • Treatment selection often relies on empirical methods due to multifactorial influences.